A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is study designed to investigate the efficacy and safety of Jaktinib in the treatment of
participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis
Area and Severity Index (PASI) score and routine safety assessments.